Funny you should mention JNJ as a possible suitor
Post# of 72446
(Total Views: 453)
Posted On: 10/21/2018 5:38:42 PM
Funny you should mention JNJ as a possible suitor to a partnership and it would be my second overall choice with big bio-pharma .
Here is some due diligence I uncovered to its possibilities to a earlier article around when BRILACIDIN was starting full bloom with UP :
Johnson & Johnson : Small biotech companies dominate the pipeline for Microbiome-targeted therapies, says GlobalData
04/20/2018 | 10:19 am
With smaller biotech companies dominating the pipeline for microbiome-targeted therapeutics, large pharma firms, such as Johnson & Johnson (J&J), are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology, according to leading data and analytics company GlobalData
The companys report Microbiome-Targeted Therapeutics in Immunology focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis, and on treatments targeting the gut microbiome for the treatment of Crohns disease, ulcerative colitis and irritable bowel syndrome (IBS).
Changes in the interaction between the human body and microorganisms or shifts in the proportion of bacterial species have the potential to have a major impact on health, from metabolism to immunity. As research on the human microbiome has so far produced few therapies, there are ample opportunities for pharma companies entering into the microbiome space,
Therapies targeting the gut microbiome lead the pipeline as of Q1 2018. There are 10 pipeline therapies in clinical development (Phase I through Phase IIb/III) targeting the gut microbiome, while there are only three pipeline therapies in clinical development (Phase I through Phase III) targeting the skin microbiome............All imho,tryz
Here is some due diligence I uncovered to its possibilities to a earlier article around when BRILACIDIN was starting full bloom with UP :
Johnson & Johnson : Small biotech companies dominate the pipeline for Microbiome-targeted therapies, says GlobalData
04/20/2018 | 10:19 am
With smaller biotech companies dominating the pipeline for microbiome-targeted therapeutics, large pharma firms, such as Johnson & Johnson (J&J), are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology, according to leading data and analytics company GlobalData
The companys report Microbiome-Targeted Therapeutics in Immunology focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis, and on treatments targeting the gut microbiome for the treatment of Crohns disease, ulcerative colitis and irritable bowel syndrome (IBS).
Changes in the interaction between the human body and microorganisms or shifts in the proportion of bacterial species have the potential to have a major impact on health, from metabolism to immunity. As research on the human microbiome has so far produced few therapies, there are ample opportunities for pharma companies entering into the microbiome space,
Therapies targeting the gut microbiome lead the pipeline as of Q1 2018. There are 10 pipeline therapies in clinical development (Phase I through Phase IIb/III) targeting the gut microbiome, while there are only three pipeline therapies in clinical development (Phase I through Phase III) targeting the skin microbiome............All imho,tryz
(1)
(0)